| 망막F-072 |
| 황반변성 환자를 대상으로 한 배아줄기세포 유래 망막색소상피세포 이식의 초기 결과 |
| 차의과학대학교 분당차병원 안과학교실(1), (주)차바이오앤디오스텍 스템셀 R&D 본부 (2) 서울 CRO (3), 건국대학교 (4), 차의과학대학교 바이오산업응용학과 (5) |
| 송원경(1), 권희정(1), 김형철(1), 정석중(1), 이재호(2), 김경순 (3), 정형민 (4), 최용수 (5), 김현주(2) |
|
목적 : To report the initial macular degeneration patients who underwent human embryonic stem cell derived retinal pigment epithelial cells (hES-RPE) transplantation in our institution
방법 : Three patients (2 Dry Age-related macular degeneration (AMD), 1 Stargardt's disease (SMD)) have received pars plana vitrectomy and subretinal hES-RPE cells injection. Patients used tacrolimus and mycophenolate mofetil for immunosuppression. ETDRS visual acuity (VA), visual field examination (VF), fundus photography, fluorescein angiography, spectral-domain OCT, electroretinography were performed.
결과 : A 79-year-old male dry AMD patient with initial VA of 1 ETDRS letter. VA was stable without subjective symptoms. A 65-year-old male dry AMD patient with initial VA of 18 ETDRS letters(snellen 20/400) had improved to 29 letters(20/250) and smaller central scotoma observed on goldman VF. A 45-year-old male SMD patient with initial VA of 1 ETDRS letters(Counting finger) had improved to 7 letters(20/800) and smaller central scotoma observed on goldman VF. No serious ocular or systemic adverse events have occurred in these patients.
결론 : Though we have experienced small number of patients, subretinal injection of hES-RPE cells seems relatively safe and may rescue vision in some patients.
|
| |